{"id":"NCT01872897","sponsor":"Reckitt Benckiser Healthcare (UK) Limited","briefTitle":"Compound Sodium Alginate Double Action Chewable Tablets 4-hour Esophageal pH Study in GERD Patients","officialTitle":"A Multi-centred, Randomised, Open Label, Placebo-controlled, Two-period Crossover Study to Evaluate 4-hour Esophageal pH Change in GERD Patients After Administration of Compound Sodium Alginate Double Action Chewable Tablets or Matching Placebo Tablets","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2013-07-02","primaryCompletion":"2013-12","completion":"2013-12","firstPosted":"2013-06-07","resultsPosted":"2025-04-29","lastUpdate":"2025-04-29"},"enrollment":45,"design":{"allocation":"RANDOMIZED","model":"CROSSOVER","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Gastroesophageal Reflux Disease"],"interventions":[{"type":"DRUG","name":"Sodium Alginate Double Action Chewable Tablets","otherNames":["Gaviscon Double Action Tablets"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Sodium Alginate Double Action Chewable Tablets, then Placebo tablets","type":"ACTIVE_COMPARATOR"},{"label":"Placebo tablets, then Sodium Alginate Double Action Chewable Tablets","type":"PLACEBO_COMPARATOR"}],"summary":"This study is being conducted to assess the effectiveness of the Compound Sodium Alginate Double Action Chewable Tablets compared to placebo on acidic reflux events into the esophagus in patients diagnosed with Gastroesophageal Reflux Disease (GERD).","primaryOutcome":{"measure":"Percentage of Time During the 4-hour Post-dosing Period With pH Below pH 4","timeFrame":"0 to 4 hours post-dose","effectByArm":[{"arm":"Sodium Alginate Double Action Chewable Tablets","deltaMin":5.14,"sd":null},{"arm":"Placebo Tablets","deltaMin":14.94,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.0003"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":1,"exclusionCount":14},"locations":{"siteCount":1,"countries":["China"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":22},"commonTop":["White blood cell count decreased"]}}